SCHEMBL23926344

SCHEMBL23926344

Oc1cnccc1-c1nc(-c2ccccc2O)n2c1CCCC2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
ALDH1A1 P00352 4/20 0.35
KDM4E B2RXH2 4/20 0.35
HPGD P15428 3/20 0.35
HSD17B10 Q99714 3/20 0.35
MAPK1 P28482 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
USP2 O75604 2/20 0.35
TSHR P16473 2/20 0.35
LMNA P02545 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
GAA P10253 3/20 0.35
MAPT P10636 4/20 0.34
GFER P55789 1/20 0.34
THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30118937 1.00 MEN1 (0.35) MEN1KMT2ACYP1A2CYP3A4CYP2C9
SCHEMBL23926347 0.92 MEN1 (0.36) MEN1KMT2ACYP1A2CYP3A4CYP2C9
SCHEMBL30118889 0.92 MEN1 (0.36) MEN1KMT2ACYP1A2CYP3A4CYP2C9
SCHEMBL23926383 0.90 HPGD (0.41) MEN1KMT2AALDH1A1KDM4EHPGD
SCHEMBL30118958 0.82 CYP2C19 (0.37) MEN1KMT2ACYP2C19ALDH1A1KDM4E
SCHEMBL23926363 0.82 CYP2C19 (0.37) MEN1KMT2ACYP2C19ALDH1A1KDM4E
SCHEMBL30118931 0.80 ADORA3 (0.39) MEN1KMT2ACYP2C19ALDH1A1KDM4E
SCHEMBL23926329 0.80 HPGD (0.41) MEN1KMT2AALDH1A1KDM4EHPGD
SCHEMBL23926385 0.80 ADORA3 (0.39) MEN1KMT2ACYP2C19ALDH1A1KDM4E
SCHEMBL30118905 0.80 HPGD (0.41) MEN1KMT2AALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4168408-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2023-04-26 EP disclosed
CN-115667256-A Compounds for treating diseases and methods of treating diseases 艾特里提治疗有限公司 2023-01-31 CN disclosed
WO-2021253091-A1 COMPOUNDS FOR AND METHODS OF TREATING DISEASES Alterity Therapeutics Limited (AU) 2021-12-23 WO disclosed
US-11155547-B1 Compounds for and methods of treating diseases Alterity Therapeutics Limited (AU) 2021-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11155547-B1 Compounds for and methods of treating diseases HTT, SNCA, PARK7 MEN1 1161/4885KMT2A 730/4885CYP1A2 3051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.